Advertisements

Nora-BE(Progesterone)

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Nora-BE(Progesterone)

Quick Facts

Property Description
Active ingredient Norethindrone (Progestin)
Form Oral Tablet
Pharmacological class Contraceptive Agent, Progestational Hormone
Common use Prevention of pregnancy (Contraception)
Origin Synthetic steroid hormone

Nora-BE: Definition and Classification as a Progestin-Only Pill

Nora-BE is a prescription-only oral contraceptive classified as a Progestin-Only Pill (POP), commonly referred to as the minipill. This medication is estrogen-free, a single-ingredient formulation that distinguishes it from Combined Oral Contraceptives. The classification places Nora-BE within the pharmacological class of Contraceptive Agents and Progestational Hormones. Its primary route of administration is oral, delivered as a tablet.

This single-ingredient composition offers an alternative for specific groups, such as lactating women or those with medical factors where estrogen is not advised. The use of Progestin-Only Pills is a recognized approach for these populations.


Composition: Active Ingredient and Synthetic Origin

The single active ingredient in Nora-BE is Norethindrone, a substance utilized as a therapeutic oral contraceptive. Norethindrone is a synthetic steroid hormone, meaning it is chemically synthesized to replicate the biological effects of natural progesterone in the body.

Norethindrone is chemically derived from a 19-nortestosterone structure and functions as the progestin in the formulation, combined with standard solid pharmaceutical excipients. As a single-ingredient product, Nora-BE provides a consistent, monophasic daily dose of the synthetic progestogen.


General Purpose: Interrupting Conception

The core purpose of Nora-BE is to provide effective contraception, which is the prevention of pregnancy. The synthetic progestogen achieves this by primarily inducing changes in the reproductive tract. This includes thickening the cervical mucus to inhibit sperm passage and altering the endometrium (uterine lining) to prevent implantation.

This strategy of relying on local effects is a defining characteristic of the Progestin-Only Pill class. The medication is intended for use by women of reproductive age to prevent pregnancy and is utilized for its effectiveness through these primary local changes.

Regulatory References

  1. Norethindrone MeSH
  2. Norethindrone DailyMed Label
  3. Progestin-Only Oral Contraceptives
  4. NORA BE- norethindrone tablet Indications
Advertisements

What side effects are possible with Nora-BE(Progesterone)?

Possible Side Effects and Safety Information

The safety profile for the progestin-only pill (POP) containing Norethindrone is documented in official government regulatory sources, classifying potential adverse reactions by frequency and organ system. The most frequently documented safety characteristic is the disturbance of menstrual bleeding patterns, which can include irregular periods, spotting, or the absence of periods (amenorrhea).

Other adverse reactions categorized as Common (occurring in ge 2% of users in clinical trials) include headache, nausea, menstrual cramps, breast tenderness or pain, mood swings, acne, and weight gain.


Serious Adverse Reactions and Safety Constraints

The regulatory label identifies several serious safety concerns and absolute prohibitions (contraindications). The most critical warnings relate to the potential for Ectopic Pregnancy if conception occurs while on the medication, and the documented risk of developing Ovarian Cysts due to delayed follicular atresia. Additionally, Hepatic Neoplasia (benign or malignant liver tumors) is listed as a major safety concern and contraindication.

The medication is contraindicated in patients with a history of breast carcinoma, acute liver disease, or undiagnosed abnormal genital bleeding. A specific safety restriction prohibits co-administration with Hepatitis C combination drug regimens (including ombitasvir, paritaprevir, and ritonavir) due to the documented risk of elevated liver enzymes.


Population-Specific Safety Notes

Specific warnings apply to certain populations. The label includes mandatory warnings regarding increased cardiovascular risk (such as heart attacks and strokes) for women who smoke and use oral contraceptives. For patients with diabetes mellitus, the label notes that a slight deterioration in glucose tolerance may occur.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

The information regarding overdose for Nora-BE is derived strictly from official government regulatory documentation, such as the FDA Prescribing Information and the European Summary of Product Characteristics (SmPC). Acute ingestion of large doses of this Progestin-Only Pill (POP) is generally classified by regulatory bodies as having low acute toxicity.


Documented Overdose Manifestations

Official labeling indicates that no serious adverse effects have been reported following the acute ingestion of excessive doses of Norethindrone. The documented clinical signs are typically limited to nausea, vomiting, and withdrawal bleeding (vaginal bleeding).

Overdose Effect Regulatory Status
Serious Adverse Effects None reported in acute cases
Antidote Availability No specific antidote is known
Required Treatment Symptomatic and supportive

Required Emergency Actions

Immediate medical attention must be sought following the ingestion of an excessive dose of Nora-BE, as mandated by regulatory authorities. Users are officially advised to contact a Poison Control Center for guidance. Treatment is solely symptomatic and supportive, aiming to manage the transient effects, as no specific pharmacological method is available to reverse the effects of the overdosage.

Advertisements

Therapeutic Uses of Nora-BE(Progesterone)

What Nora-BE (Norethindrone) Treats: Main Uses and Benefits

Nora-BE is commonly used in therapeutic domains related to preventative reproductive health and hormonal support for certain patient profiles. The medication is generally used to assist with hormonal contraception for women of reproductive age seeking family planning.

This progestin-only formulation plays a role in managing the risk of unintended pregnancy, which is the core therapeutic goal. The use of progestin-only oral contraceptives for this purpose is relevant in therapeutic contexts where preventative support is needed.

Nora-BE is also relevant for managing unique clinical needs: it is commonly used when patients must avoid estrogen exposure, such as those with a history of blood clots or certain migraines. This option supports family planning in clinical settings where patients experience heightened risks associated with estrogen, and it is considered relevant for patient groups that include lactating women.

Additionally, Nora-BE is applied in addressing associated symptoms like heavy bleeding and painful periods. This may assist with maintaining functional stability and supports general comfort during symptomatic periods.


Quick Fact: Use in Symptom Management

Nora-BE plays a role in managing symptoms related to disruptive menstrual manifestations and is applied in clinical settings that involve estrogen-sensitive patient profiles where supportive symptomatic management is appropriate.

Regulatory References

  1. FDA DailyMed official label for Norethindrone
Advertisements

Eligibility and Restrictions for Use

Eligibility Profile: Who Can and Cannot Use Nora-BE (Norethindrone)

The eligibility criteria for Nora-BE are strictly defined by regulatory authorities and center on age, reproductive status, and specific medical conditions. The medication is indicated for use by females of reproductive age seeking contraception.

Eligibility Scope Official Regulatory Statement
Populations Allowed Females of reproductive age for contraception. Supported for use by nursing mothers as an estrogen-free option.
Absolute Contraindications Known or suspected pregnancy; known or suspected carcinoma of the breast; undiagnosed abnormal genital bleeding; acute liver disease or liver tumors.
Age-Related Rules Use is not indicated before the onset of menstruation (menarche) and is generally not applicable to older adults.
Condition-Specific Rules Use is contraindicated in the presence of acute liver disease or liver tumors. Patients with diabetes or a history of ectopic pregnancy require specific monitoring.

Eligibility Classifications (High-Level) Regulatory Basis
Severity Classification Contraindication (Absolute Exclusion); Indicated Use (Approved Population); Conditional Use (Required Monitoring/Caution).
Eligibility-Context Constraints Restricted to the contraceptive indication. Prohibited if the cause of abnormal bleeding remains undiagnosed.

The official eligibility profile strictly prohibits the use of Nora-BE in individuals with specific conditions, primarily concerning liver health, hormone-sensitive cancers, and pregnancy status. Use is limited to the reproductive years, and the contraceptive effectiveness may be reduced when certain enzyme-inducing medicines are taken concurrently.

Advertisements

What should I know about interactions with other medicines?

Nora-BE (norethindrone) can interact with several other medications and products, potentially reducing its contraceptive effectiveness or increasing the risk of side effects. It is critical to inform your healthcare provider about all prescription drugs, over-the-counter medicines, and herbal supplements you are taking.

Medications that May Decrease Effectiveness

The primary concern is with drugs that induce liver enzymes, particularly the CYP3A4 system, which accelerates the breakdown of norethindrone. This can lower the hormone's concentration in the body, leading to breakthrough bleeding and possible pregnancy. Examples of these medications include:

  • Anticonvulsants: Such as carbamazepine, phenytoin, and phenobarbital.
  • Certain Antibiotics: Specifically rifampin and rifabutin (rifamycins).
  • HIV/AIDS Medications: Certain protease inhibitors and non-nucleoside reverse transcriptase inhibitors, such as efavirenz.
  • Herbal Products: St. John's wort (Hypericum perforatum).

If you must take these medications, a non-hormonal form of contraception (e.g., condoms, diaphragm) should be used as a backup method.

Other Potential Interactions

  • Azole Antifungals: Medications like fluconazole or voriconazole can inhibit the breakdown of norethindrone, potentially increasing its concentration and the risk of side effects.
  • Grapefruit Juice: Consuming grapefruit juice may also inhibit the CYP3A4 enzyme in the gut wall, leading to increased norethindrone levels.
Advertisements

Mechanism of Action

Norethindrone in Nora-BE works by binding to Progesterone Receptors (PRs) across the reproductive system, initiating three primary physiological constraints that collectively modulate the sequence of events of the reproductive process. This multiple-mechanism approach integrates systemic and local actions, utilizing peripheral effects as primary constraints on the reproductive process.

Inducing a Physical Barrier via Cervical Mucus Modulation

Norethindrone acts peripherally by targeting PRs in the cervical glandular tissue. This agonistic action initiates molecular changes that increase the viscosity and density of the cervical mucus, transforming it into a thick, cellular plug. This localized mechanism creates a physical barrier that severely limits sperm motility and penetration into the upper reproductive tract, functioning as a significant, localized constraint on sperm passage.

Preventing Nidation through Endometrial Transformation

The drug also acts directly on the endometrium (uterine lining), causing it to become prematurely altered (decidualized) and subsequently atrophic (thin). This PR-mediated tissue transformation renders the lining biochemically and structurally unsuitable for supporting a blastocyst. This peripheral mechanism provides a secondary physiological action by modulating the conditions required for nidation.

Constraining the Ovarian Cycle via Neuroendocrine Feedback

Systemically, Norethindrone exerts negative feedback on the Hypothalamic-Pituitary-Ovarian (HPO) axis, which suppresses or modifies the mid-cycle surge of Luteinizing Hormone (LH). While this central mechanism is variable and does not consistently inhibit follicular rupture in every cycle, this mechanism provides a supplementary physiological action that constrains the cycle through the suppression or modification of the LH surge.

Advertisements

Dosage and Administration Information

Official Administration Guidelines

Nora-BE is administered exclusively by the oral route as a tablet containing 0.35 mg of the progestin Norethindrone. The official usage protocol for this progestin-only pill (POP) dictates a standard daily dose of one tablet. This regimen establishes the general principle of use: the medication is to be taken once a day, and its efficacy relies heavily on consistent timing of administration.

The fundamental pattern of use for Nora-BE is continuous. This means administration is uninterrupted, with no scheduled break days between the 28-day pill packs. The tablet may be taken with or without food according to patient preference.

Maintaining a strict daily schedule is a key administration requirement. Regulatory guidance specifies that if a dose is taken more than three hours later than the scheduled time, the reliability of the regimen is affected. In this event, official procedural instructions mandate the immediate use of a backup non-hormonal method for the subsequent 48 hours.

In terms of specific patient contexts, postpubertal adolescents follow the identical 0.35 mg daily dosing schedule. For women who are breastfeeding, the initiation of Nora-BE is supported starting six weeks following delivery.

Usage Constraint Official Requirement (Norethindrone 0.35 mg)
Administration Route Oral administration
Dosing Frequency Once daily, at the same time every day
Cycle Pattern Continuous (no break between packs)
Missed Dose Limit More than 3 hours late requires backup method for 48 hours
Advertisements

Recent Clinical Evidence

Recent Clinical Evidence Overview

Nora-BE contains norethindrone, a progestin-only hormone formulation. Clinical research on this class of medication focuses primarily on its established use as a contraceptive agent and its suitability for women who cannot use estrogen-containing methods.

Contraceptive Efficacy

Clinical trials have established the efficacy of norethindrone in preventing pregnancy. The mechanism involves thickening the cervical mucus, which hinders sperm penetration, and altering the uterine lining to prevent the implantation of a fertilized egg. While progestin-only pills are effective, their contraceptive reliability is highly dependent on strict adherence to a 24-hour dosing schedule, as indicated by clinical guidance.

Safety and Tolerability Profile

Studies have investigated the safety profile of progestin-only pills, particularly for women who are breastfeeding or have certain medical conditions, such as a history of estrogen-sensitive cancers or a risk of thromboembolism, where estrogen is typically contraindicated. Key findings from clinical summaries indicate:

  • Irregular Bleeding: The most common alteration in the menstrual cycle is the occurrence of irregular or unpredictable bleeding, spotting, or sometimes amenorrhea (absence of periods).
  • Adverse Events: Commonly reported side effects in clinical trials include headache, breast tenderness, nausea, and changes in weight. These effects are generally considered mild and often decrease over time.
  • Risk Factors: Research continues to evaluate the effects of progestins on factors such as lipid profiles and bone density. Women with pre-existing conditions like liver disease or a history of depression are typically advised to discuss their individual health profile with a physician before starting this medication.

Evidence for Nora-BE is consistent with the established profile of low-dose, progestin-only oral contraceptives. Individual responses to hormonal medications can vary, and clinical guidance emphasizes the importance of routine medical follow-up.

Key Studies & References

  1. Label: NORA BE- norethindrone tablet (US FDA Approved Drug Label)
  2. Effectiveness and efficacy rates of progestin-only pills: A comprehensive literature review
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Nora-BE(Progesterone) (FAQ)


Q: How does the effectiveness of Nora-BE compare to combination birth control pills?

A: Official information indicates that Nora-BE is generally considered effective for preventing pregnancy. Progestin-only pills like this one are described in medical sources as being approximately 91% effective with typical use. Combination oral contraceptives generally have a higher efficacy rate. For all hormonal contraceptives, the reliability depends on strictly following the daily dosing schedule.


Q: Why is Nora-BE sometimes called a 'mini-pill'?

A: Nora-BE is formally classified as a Progestin-Only Pill (POP). It is often referred to as a 'mini-pill' because it contains a lower dose of hormones compared to combination birth control pills, which use both estrogen and a progestin.


Q: Is Nora-BE commonly prescribed for uses other than preventing pregnancy?

A: Nora-BE is indicated primarily for the prevention of pregnancy. However, official information notes that certain forms of the active ingredient (norethindrone) are also prescribed to address issues like abnormal vaginal bleeding caused by hormonal imbalances or for endometriosis. The specific uses depend on the approved formulation and dosage of the drug.


Q: How long do common side effects like nausea or breast tenderness usually last after starting Nora-BE?

A: Regulatory summaries note that common side effects, such as headache, breast tenderness, or nausea, are usually considered mild. These effects are generally considered mild and often decrease or subside as use continues, particularly within the initial months. An exact duration for symptom resolution is not specified in regulatory documentation, as individual experiences can vary.


Q: What is the risk of developing ovarian cysts while using Nora-BE?

A: Official warnings note a risk of developing fluid-filled sacs on the ovaries, known as ovarian cysts, while using progestin-only pills. Regulatory information indicates these cysts are generally non-malignant and often resolve on their own without requiring intervention.


Q: What should be done if I experience vomiting or severe diarrhea shortly after taking Nora-BE?

A: Official guidance states that if vomiting or severe diarrhea occurs less than two to four hours after taking the pill, the absorption may be affected, and this should be treated as a missed pill. Official guidance requires that in this situation, the user should refer to the instructions for a missed dose.


Q: If I miss a pill, how is the effectiveness of Nora-BE affected?

A: Taking a pill more than three hours later than the scheduled time is considered a missed pill and can increase the risk of pregnancy. The guidance specifies that the late pill should be taken as soon as remembered, and a backup non-hormonal contraceptive method is required for the subsequent 48 hours to maintain effectiveness.


Q: Is Nora-BE used to treat conditions like endometriosis or abnormal uterine bleeding?

A: Nora-BE is indicated for contraception. However, official information shows that the active ingredient, norethindrone, is also approved in certain drug formulations for the treatment of endometriosis and abnormal uterine bleeding caused by hormonal imbalance.


Q: Does Nora-BE have any effect on acne or skin conditions?

A: Regulatory documents list acne as a documented side effect, indicating a potential change in skin condition. Dark, blotchy spots on sun-exposed skin, known as melasma, are also noted in some regulatory summaries as a possible adverse reaction.


Q: What types of long-term studies have been conducted on the safety of progestin-only pills like Nora-BE?

A: Clinical summaries indicate that research continues to evaluate the long-term safety profile of progestin-only pills. This ongoing research includes examining potential effects on factors such as lipid profiles and bone density.


Q: Is there information about Nora-BE's use in individuals with conditions like asthma, high blood pressure, or high cholesterol?

A: Regulatory labels state that use should be approached with caution in patients with a history of high cholesterol or diabetes mellitus. High blood pressure may also require monitoring, as hormonal contraceptives can sometimes cause or worsen existing hypertension.


Q: Does Nora-BE affect bone density over time?

A: Official documentation notes that research continues to evaluate the effects of progestins on bone mineral density (BMD). The effect of a low-dose oral progestin like norethindrone on long-term bone density is subject to ongoing study, and established findings are being tracked.


Q: Is it a common experience to have bloating while on Nora-BE?

A: Regulatory-based summaries list stomach pain or bloating as a general adverse event that some users may experience. Individual experiences of side effects can vary.


Q: Could Nora-BE increase my blood pressure?

A: Regulatory information indicates that hormonal contraceptives can, in some users, increase blood pressure or worsen existing high blood pressure. Official information indicates that monitoring of blood pressure may be required for users with pre-existing hypertension or related conditions.


Q: What should I know about using Nora-BE if I have a history of seizures or epilepsy?

A: Regulatory guidance indicates that the medication requires caution in patients with a history of seizures or epilepsy, as these conditions may be affected by hormonal contraceptives. Furthermore, certain antiepileptic drugs can reduce the effectiveness of the pill.


Q: Does Nora-BE contain any inactive ingredients that commonly cause allergic reactions?

A: The inactive ingredients listed in the official labeling include common components such as lactose anhydrous, lactose monohydrate, and corn starch. Hypersensitivity (an allergic reaction) to any component of the product, whether active or inactive, is listed as a contraindication.


Q: Are there any known interactions between Nora-BE and grapefruit or grapefruit juice?

A: Official information indicates that grapefruit and grapefruit juice may cause an increase in the blood levels of norethindrone. Some official summaries advise users to limit consumption of these products while taking the medication, based on the potential for increased drug levels.


Q: What are the signs of a serious, though rare, side effect, like a blood clot, associated with progestin-only pills?

A: Although the overall risk is low with progestin-only pills, patients using hormonal contraceptives are advised by regulatory guidance to seek immediate medical attention for signs such as sudden severe headache, pain/swelling/tenderness in an arm or leg, chest pain, or trouble breathing.


Q: Is Nora-BE less effective if I am slightly off the exact same time each day?

A: The efficacy of Nora-BE is highly dependent on consistent timing. Regulatory documents establish a critical window of three hours for late doses; taking the pill outside this window requires backup protection. To ensure maximum contraceptive reliability, a strict daily administration time is required; variations within the three-hour window are subject to professional guidance.

Advertisements

How should Nora-BE(Progesterone) be stored and disposed of?

Storage and Disposal of Nora-BE (Norethindrone)

The storage of Nora-BE tablets must strictly adhere to the conditions specified in the official labeling to maintain stability. Nora-BE must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), with permitted excursions between 15 C and 30 C.


Key Requirements

  • Protection: The medication must be protected from light and stored in its original container.
  • Child Safety: It is mandatory to keep Nora-BE out of the reach of children.
  • Disposal: Unused or expired Nora-BE must be disposed of according to local regulations. Medication should not be discarded by flushing it down a toilet or pouring it down a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Nora-BE(Progesterone) found in:

A-Z Index: